Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yinglitinib
- Development stage
- Unknown
- Lead developer
- Sunshine Lake Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yinglitinib (DNT04110) is an orally bioavailable, small molecule multi-target tyrosine kinase inhibitor (TKI) developed by Guangdong Dongyangguang Pharmaceutical (HEC Pharm). It is designed to inhibit several key kinases involved in tumor growth and angiogenesis, specifically targeting the vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), platelet-derived growth factor receptors (PDGFR), and the mast/stem cell growth factor receptor (c-Kit). By blocking these signaling pathways, yinglitinib aims to suppress the formation of new blood vessels that supply tumors and directly inhibit cancer cell proliferation. The drug has been investigated in Phase I clinical trials in China for the treatment of advanced malignant solid tumors.
- Other names
- yinglitinib maleate
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on yinglitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yinglitinib.